Immunoblot assay showed that combination treatment clearly upregulated expressions of LC3-, Beclin-1, cleavad-caspase 7 and -PARP, and downregulated SQSTM1 expression compared to single treatment in xenograft tumor specimens (Figure 7D), which were in consistent with the finding in vitro (Figure 4C and 4F). The gene discussed is MAP1LC3A; the disease is neoplasm.